Updated COVID-19 vaccines from BioNTech and Pfizer are available. Here is a brief update on the market landscape:

Pfizer has substantial supply of 2023-2024 Formula COVID-19 vaccines and does not have any shortages at this time.
Following FDA approval and emergency use authorization, the CDC issued recommendations the week of September 11, 2023.
Pfizer has shipped and delivered several million doses of 2023-2024 Formula COVID-19 vaccines. We continue to fulfill orders and anticipate delivering millions of additional doses each week.
Pfizer is actively working with our Wholesaler and Distributors partners and customers to help ensure access by shipping product directly to customers when and where needed.

Regarding reimbursement, there may be confusion related to reimbursement for COVID-19 vaccines and out of pocket costs to patients. Under Section 3203 of the CARES Act and subsequent U.S. government guidance, most commercial health plans (excluding ACA grandfathered plans), must cover updated ACIP-recommended COVID-19 vaccines and their administration with no patient cost-sharing immediately upon approval or authorization for emergency use. As a result, commercial health plans must cover and reimburse claims for the updated Pfizer-BioNTech COVID-10 vaccines (2023-24 formula) as of the date of FDA approval and emergency use authorization on September 11, 2023.

In July 2023, HHS issued guidance to payors to prepare to cover COVID-19 vaccination with the onset of the COVID-19 vaccine Commercialization. To review this letter click on the attached link Letter from HHS Secretary on COVID-19 Vaccine Coverage | HHS.gov

Click here to request a call from a Pfizer Vaccines Representative for information about updated COVID-19 vaccines from BioNTech and Pfizer or contact Tina Clark, your local Pfizer Vaccines Representative.